STOKStoke Therapeutics, Inc.
$24.71+7.9% 1Y
$24.71
$22.3752 weeks$38.35
The financials
Stoke Therapeutics, Inc. by the numbers
Stoke Therapeutics, Inc. (STOK) reported revenue of $9.3M in Q2 2026 (quarter ended Jun 30, 2026), down 33% from the same quarter a year earlier. That came with net loss of $62M. For the full year FY2025, revenue was $184M (+405% year on year) and net income −$6.9M. Its largest product in Q1 2025 (quarter ended Mar 31, 2025) was IP License at $151M, 99% of the disclosed total, well ahead of Global Development Activity at 1.1%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $9.3M | $14M | −33% |
| Operating income | −$65M | −$27M | n/a |
| Net income | −$62M | −$23M | n/a |
| Diluted EPS | −$0.93 | −$0.40 | n/a |
| Product | Revenue | Share |
|---|---|---|
| IP License | $151M | 99% |
| Global Development Activity | $1.6M | 1.1% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $4.0M (-32%)
Global Development Activity grew +146% year on yearIP License -100% year on year
Segment Latestquarter on quarteryear on year
- Global Development Activity$4.0M$4.0Mquarter on quarter -32%year on year +146%-32%+146%
- IP License$0.00$0.00quarter on quarter n/ayear on year -100%n/a-100%
On our screens:Most shorted stocks